Unknown

Dataset Information

0

HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.


ABSTRACT: Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.1. Discuss the mode of action of the three CDK4/6 inhibitors in late clinical development: palbociclib (PD-0332991; Pfizer), ribociclib (LEE011; Novartis), and abemaciclib (LY2835219; Lilly). 2. Describe the efficacy and safety data relating to their use in HR+, HER2- advanced breast cancer. 3. Discuss the key side effects associated with CDK4/6 inhibitors along with considerations for adverse event management and patient monitoring.Relevant information and data were assimilated from manuscripts, congress publications, and online sources.CDK4/6 inhibitors have demonstrated improved progression-free survival in combination with endocrine therapy compared with endocrine therapy alone. The side-effect profile of each agent is described, along with implications for patient monitoring, and considerations for patient care providers and pharmacists.Addition of a CDK4/6 inhibitor to endocrine therapy increases efficacy and delays disease progression. Insight into the unique side-effect profiles of this class of agents and effective patient monitoring will facilitate the successful use of CDK4/6 inhibitor-based therapies in the clinic.

SUBMITTER: Sammons SL 

PROVIDER: S-EPMC5652078 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.

Sammons Sarah L SL   Topping Donna L DL   Blackwell Kimberly L KL  

Current cancer drug targets 20170101 7


<h4>Background</h4>Cyclin-dependent kinase (CDK) 4/6 inhibitor-based therapies have shown great promise in improving clinical outcomes for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.<h4>Objectives</h4>1. Discuss the mode of action of the three CDK4/6 inhibitors in late clinical development: palbociclib (PD-0332991; Pfizer), ribociclib (LEE011; Novartis), and abemaciclib (LY2835219; Lilly). 2. Describe the effica  ...[more]

Similar Datasets

| S-EPMC10110597 | biostudies-literature
| S-EPMC5818877 | biostudies-literature
| S-EPMC7280088 | biostudies-literature
| S-EPMC6295674 | biostudies-literature
| S-EPMC8954717 | biostudies-literature
| S-EPMC11337580 | biostudies-literature
| S-EPMC9355808 | biostudies-literature
| S-EPMC10340287 | biostudies-literature
| S-EPMC10491615 | biostudies-literature
| S-EPMC6449170 | biostudies-literature